Sage Therapeutics says rare disease drug found to be safe in mid-stage study

,
June 11 (Reuters) – Sage Therapeutics (SAGE.O) said on Tuesday its experimental drug was found to be safe and showed some effect in patients with a rare, genetic neurological condition called Huntington’s disease in a part of a mid-stage study.
 
The company, however, said the study in Huntington’s disease patients was not designed to show a statistically significant difference between the drug dalzanemdor and placebo.
 
Shares of the company, which soared 80% initially, erased those gains and were down 1.6% in volatile premarket trading.
 
The news follows a mid-stage trial failure for the same drug, in April when it was tested in patients with Parkinson’s disease.

Source: Reuters

/by
You might also like
x-ray, handIpsen wins FDA’s adcomm support for rare disease drug
FDAFDA approves Genzyme’s Xenpozyme, first treatment for rare genetic disease acid sphingomyelinase deficiency
AstraZenecaAstraZeneca’s Imfinzi fails in late-stage trial to treat certain lung cancers
Adult holds child's handUltragenyx eyes pivotal study after mid-stage win in Angelman syndrome
artificial intelligenceBias in artificial intelligence: How can we minimize it?
Ocugen-Bharat Biotech COVID vaccine meets main goals in U.S. trial
BayerBayer to seek approval for menopausal relief drug after third trial win
Adult holds child's handChimerix’s drug candidate improves survival for patients with incurable brain tumor